Historical Summaries & Sentiment Tracking
cards show the S&P 500's daily move · scroll horizontally → · tracking since Apr 30, 2026
Regime: Risk-On +32
1d · nascent
Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.
Risk-On · supportive
Neutral
Risk-Off · headwind
Stress · fear
Fri
1
7,209
7,229
+0.28%
+1.0
Sat
2
Sun
3
Mon
4
7,230
7,201
-0.40%
-1.1
Tue
5
7,201
7,260
+0.83%
+2.0
Wed
6
7,259
7,366
+1.48%
+2.9
Thu
7
7,365
7,337
-0.38%
-1.1
Fri
8
7,337
7,397
+0.82%
+2.0
Sat
9
Sun
10
Mon
11
7,399
7,413
+0.19%
+0.8
Tue
12
7,413
7,402
-0.15%
-0.6
Wed
13
7,401
7,445
+0.59%
+1.6
Thu
14
7,444
7,502
+0.78%
+1.9
Fri
15
7,501
7,409
-1.23%
-2.3
Sat
16
Sun
17
Mon
18
7,409
7,403
-0.07%
-0.4
Tue
19
7,403
7,355
-0.65%
-1.5
Wed
20
7,354
7,433
+1.08%
+2.3
Thu
21
7,433
7,446
+0.18%
+0.7
Fri
22
7,446
7,474
+0.38%
+1.2
Sat
23
Sun
24
Mon
25
7,446
7,473
+0.37%
+1.2
Tue
26
7,473
7,519
+0.62%
+1.6
Wed
27
7,519
7,521
+0.03%
+0.2
Thu
28
7,520
7,563
+0.57%
+1.6
Fri
29
7,564
7,581
+0.23%
+0.9
Sat
30
Sun
31
Mon
1
7,580
7,600
+0.27%
+0.9
Tue
2
7,600
7,611
+0.14%
+0.6
Wed
3
7,610
7,557
-0.70%
-1.6
Thu
4
7,554
7,585
+0.41%
+1.3
Fri
5
7,580
7,384
-2.59%
-3.7
Sat
6
Sun
7
Mon
8
7,600
7,406
-2.56%
-3.7
Tue
9
7,610
7,387
-2.93%
-4.0
Wed
10
7,554
7,267
-3.80%
-4.7
Thu
11
7,584
7,394
-2.51%
-3.6
Fri
12
7,384
7,431
+0.65%
+1.7
Sat
13
Sun
14
Mon
15
7,406
7,554
+2.01%
+3.5
Tue
16
7,387
7,511
+1.69%
+3.1
Wed
17
7,267
7,420
+2.11%
+3.6
Thu
18
7,394
7,501
+1.44%
+2.8
Fri
19
7,394
7,501
+1.44%
+2.8
Sat
20
Sun
21
Mon
22
7,431
7,473
+0.56%
+1.5
Tue
23
7,554
7,365
-2.50%
-3.6
Wed
24
7,511
7,358
-2.04%
-3.2
Thu
25
7,420
7,357
-0.84%
-1.8
Fri
26
7,501
7,354
-1.95%
-3.1
Sat
27
Sun
28
Mon
29
7,473
7,440
-0.43%
-1.2
Tue
30
7,365
7,499
+1.82%
+3.3
Wed
1
7,358
7,483
+1.70%
+3.2
Thu
2
7,357
7,483
+1.71%
+3.2
Fri
3
7,357
7,483
+1.71%
+3.2
Sat
4
Sun
5
Mon
6
7,354
7,537
+2.49%
+4.1
Tue
7
7,440
7,504
+0.85%
+2.0
Wed
8
7,499
7,483
-0.22%
-0.7
Thu
9
7,483
7,544
+0.81%
+1.9
Fri
10
7,483
7,575
+1.23%
+2.6
Sat
11
Sun
12
Mon
13
7,537
7,515
-0.29%
-0.9
Tue
14
7,504
7,544
+0.53%
+1.5
Wed
15
7,483
7,572
+1.20%
+2.5
Thu
16
7,544
7,534
-0.13%
-0.5
Fri
17
7,575
7,458
-1.55%
-2.6
Sat
18
Sun
19
Mon
20
7,515
7,443
-0.96%
-1.9
Tue
21
7,544
7,509
-0.46%
-1.2
Wed
22
7,572
7,499
-0.97%
-1.9
Thu
23
7,534
7,408
-1.67%
-2.8
Fri
24
7,458
7,412
-0.61%
-1.4
Sat
25
Sun
26
Mon
27
7,443
7,413
-0.40%
-1.1
Tue
28
7,509
7,429
-1.07%
-2.1
Wed
29
7,499
7,316
-2.44%
-3.5
Thu
30
7,408
7,438
+0.40%
+1.2
Fri
31
7,412
7,490
+1.05%
+2.3
Sat
1
Sun
2
Mon
3
7,413
7,601
+2.53%
+4.1
Tue
4
7,429
7,737
+4.14%
+5.6
Wed
5
7,316
7,724
+5.57%
+6.8
Thu
6
7,438
7,710
+3.66%
+5.2
Fri
7
7,490
7,758
+3.58%
+5.1
Sat
8
Sun
9
Mon
10
7,601
7,753
+2.01%
+3.5
Tue
11
7,737
7,728
-0.11%
-0.5
Wed
12
7,724
7,749
+0.32%
+1.1
Thu
13
7,710
7,799
+1.15%
+2.5
Fri
14
7,758
7,786
+0.36%
+1.2
Sat
15
Sun
16
Mon
17
7,753
7,745
-0.10%
-0.5
Tue
18
7,728
7,692
-0.47%
-1.2
Wed
19
7,749
7,708
-0.52%
-1.3
Thu
20
7,799
7,641
-2.02%
-3.1
Fri
21
7,786
7,674
-1.43%
-2.5
Sat
22
Sun
23
Mon
24
Tue
25
Wed
26
Thu
27
Fri
28
Sat
29
Sun
30
Mon
31
Market Recap · August 14, 2026
Up Day
Divergent High- 50% Extreme dispersion and sector rotation marked the day as 50 gainers averaged +27.99% while 50 losers plunged -29.88%, with healthcare dominating winners (38% of gainers) and technology dominating losers (37% of losers), signaling a sharp rotation out of mega-cap growth into beaten-down cyclicals and biotech.
- 35% Small caps and mid-caps outpaced large-cap indices significantly—Russell 2000 +1.12%, S&P MidCap 400 +1.07%—while S&P 500 gained only +0.36% and Nasdaq Composite +0.14%, reflecting a broad reallocation away from the tech-heavy upper tier despite an overall positive close.
- 15% VIX dropped 7.83% to 14.25 on a mixed-direction tape, and five debutant gainers including Safe Pro AI (news-grounded +54% on government AI contracts) and Harte-Hanks (+50.17% on merger news) re-entered the top list after long absences, signaling selective deal activity and sector-specific momentum in beaten-down pockets.
Market Regime
Risk-On conf: medium macro · prototype+52
VIX14.3 p1
Drawdown-0.2%
Held10d · established
SinceAug 3
Top drivers:
VIX percentile ▲
S&P vs 20d avg ▲
S&P vs 50d avg ▲
Market Indexes
13
S&P 500
7,785.76
+28.12
+0.36%
Dow Jones
53,732.41
−304.52
-0.56%
NASDAQ Composite
26,729.16
+38.54
+0.14%
NASDAQ 100
30,046.14
+323.84
+1.09%
DJ US Total Market
77,212.95
+358.87
+0.47%
Russell 1000
4,245.65
+17.66
+0.42%
S&P MidCap 400
3,926.98
+41.41
+1.07%
Russell 2000
3,068.42
+33.93
+1.12%
Russell 2500
1,309.98
+4.65
+0.36%
Russell 3000
4,433.85
+19.73
+0.45%
Nasdaq Financial-100
7,658.97
−18.84
-0.25%
NIFTY 50
24,366.00
−217.80
-0.89%
VIX
14.25
−1.21
-7.83%
Biggest Gainers
50No news headlines were found in the last 48 hours to explain the 56.31% surge in BANL stock, suggesting the catalyst may be a delayed market reaction, technical event, or undisclosed development.
The absence of recent Yahoo Finance headlines makes it difficult to pinpoint a specific catalyst for this exceptional single-day gain. CBL International Limited is a commercial real estate and retail-focused business, which can be sensitive to sector rotation, interest rate expectations, or capital structure changes. For a stock ranked 1 among daily gainers with no contemporaneous news, the most likely explanations fall into a few categories: first, a delayed market reaction to an announcement made before the 48-hour window; second, a short squeeze or technical momentum event if the stock carries a significant short interest; third, an earnings release, guidance update, or material corporate action that has not yet been indexed by the RSS feed; or fourth, sector-wide positive sentiment in retail or real estate. Without corroborating headlines or structural details about BANL's capital structure, any explanation remains speculative.
Safe Pro reported record 1,336% revenue growth in Q2 2026 driven by multiple government AI contracts, with 75% gross margins on its computer vision technology, directly triggering the 54% single-day gain.
The headline released on 2026-08-14 at 12:03 UTC announces Safe Pro's Q2 2026 earnings results featuring exceptional revenue acceleration attributed specifically to government contracts for AI-powered threat detection and mapping systems. The company also reported gross margins of 75% on its AI business segment, indicating strong unit economics and pricing power in military and defense applications. This combination of triple-digit revenue growth, major government wins, and exceptional profitability metrics represents a material positive catalyst that clearly justifies institutional and retail buying interest on the day of release. The stock's ranking as the second-biggest gainer suggests the market viewed these results as sufficiently surprising or compelling relative to prior expectations.
No news headlines were published in the last 48 hours, so the cause of the 53.37% jump cannot be identified from available reporting. The move may reflect earnings, guidance, insider activity, short covering, or market rumors.
Despite CNFR ranking as the third-biggest gainer on August 14, 2026, no financial news headlines appeared in the Yahoo Finance RSS feed for the preceding 48 hours. This disconnect between significant price action and public news coverage is common in smaller-cap equities and can occur for several reasons. The catalyst could be an earnings surprise or guidance revision disclosed after market close on August 13 or before open on August 14, technical short covering if the stock had elevated short interest, an unconfirmed acquisition rumor, insider buying, or sector rotation. Without access to the actual news, regulatory filings, or real-time social media sentiment, pinpointing the specific cause is not possible from the information provided.
CDTGCDT Environmental Technology Investment Holdings Limited ordinary shares
Industrials
$2.09
+$0.79
+52.67%
No news headlines were available in the last 48 hours to explain the 52.67% gain, so the catalyst remains unclear without access to additional information sources or market data.
The absence of recent news headlines for CDTG makes it difficult to identify a specific fundamental catalyst for today's sharp 52.67% rally. CDT Environmental Technology Investment Holdings is a smaller-cap environmental technology company, and stocks in this category can be sensitive to several types of events that may not be immediately captured in major news feeds: regulatory approvals or environmental policy announcements, contract awards or partnership announcements, short-covering rallies if the stock has been heavily shorted, technical breakouts above resistance levels that trigger momentum buying, or delayed market reaction to information released outside standard news channels. Without confirmed headlines or structural insight into the stock's current technical or capital structure dynamics, the specific driver of today's move cannot be determined from available evidence.
Harte-Hanks announced a definitive merger agreement to be acquired by Star Equity Holdings for $5.00 per share in an all-cash and preferred stock deal, representing approximately a 100% premium, directly explaining the 50% stock price jump.
The headline announces a completed merger agreement where Star Equity Holdings will acquire Harte-Hanks at $5.00 per share, consisting of 50% cash and 50% Star Equity 10% preferred stock. This transaction price represents roughly double the unaffected share price prior to deal announcement. The stock closed at $4.29, which sits below the deal price, a common occurrence when merger deals carry execution risk or when the market prices in a small probability that the transaction fails to close. The deal is also expected to drive cost synergies and earnings accretion for the acquirer. This is a straightforward M&A-driven move with clear causation directly tied to the news headline.
Eton Pharmaceuticals surged 43.71% after reporting Q2 2026 revenue of $37.6 million (99% growth), beating estimates, and raising full-year guidance from $120M+ to $145M+, with analysts calling the new guidance conservative.
The headlines establish a clear and material catalyst: Eton reported second-quarter earnings on August 13–14 that significantly exceeded consensus expectations on both earnings and revenue. The company achieved 99% year-over-year revenue growth driven by the relaunch of HEMANGEOL and strength in its pediatric endocrinology and rare-disease portfolio. Most importantly, management raised full-year 2026 revenue guidance to exceed $145 million, up from the prior forecast of more than $120 million. This $25 million upward revision is substantial on a mid-size biotech base. Multiple analysts publicly stated that the raised guidance appears conservative, suggesting further upside potential. The stock's ascent to a record high aligns directly with these beats and the positive analyst commentary, with the market rewarding both the strong operational execution and apparent management confidence implied by the raised outlook.
No news headlines were found in the last 48 hours, so the 41.57% gain likely reflects either delayed reporting of an announcement, a technical or short-squeeze event, or sector-wide momentum in micro-cap stocks.
The absence of any Yahoo Finance headlines in the 48 hours preceding this sharp 41.57% jump makes direct attribution impossible. VisionWave is a micro-cap NASDAQ stock trading at $1.78, a category often susceptible to technical rebounds after heavy selling, short-squeeze activity, or delayed disclosure of material events that may not yet be widely syndicated. The stock's low price and rank as the seventh biggest gainer suggest retail or momentum-driven participation. Possible categories include: a delayed press release or SEC filing that reached only specialized channels initially, a reversal of negative technicals or options expiration dynamics, or simple momentum contagion within a cohort of beaten-down small caps. Without corroborating news, the catalyst remains speculative.
The +40% surge in SST (a short-term Treasury ETF) cannot be explained by the provided news, which concerns System1 earnings, a completely unrelated company. The move is likely driven by a sharp decline in short-term U.S. Treasury yields.
A critical issue exists here: the news headline references System1 (also ticker SST), a digital marketing company reporting poor Q2 earnings, not the SPDR Bloomberg Barclays Short-Term Treasury ETF. These are different securities with the same ticker on different exchanges. For the Treasury ETF, a 40% single-day gain is extraordinarily large and almost certainly reflects a dramatic move in underlying short-term Treasury yields—specifically a sharp decline in yields, which drives up bond prices. Short-duration Treasury ETFs are sensitive to Fed policy shifts, recession fears, flight-to-safety dynamics, or major economic data surprises. Without access to Treasury market data or broader financial headlines from August 12–14, 2026, we cannot pinpoint the specific catalyst, but the magnitude suggests a significant macro event occurred during this window.
FiEE Inc announced second quarter and first half 2026 unaudited financial results on August 14, likely driving the 35% gain as positive earnings or updated guidance reversed prior weakness in this technology stock.
The headline confirms that FiEE Inc, a technology company focused on IoT, connectivity, and AI-driven brand management solutions, released its Q2 and first-half 2026 financial results on the same date as the 35% price jump. The headline does not specify whether earnings beat or missed analyst expectations, nor does it disclose guidance changes, margin improvements, or other quantitative details. However, the timing is direct: an earnings announcement on August 14 with a major same-day rally strongly suggests the market viewed the results favorably. The magnitude of the gain (35%) is substantial and implies either strong earnings surprise, positive forward guidance, or positive sentiment shift in the technology/IoT sector. Without access to the full earnings release text or consensus estimates, we cannot confirm the specific catalyst within the results, but the correlation between announcement and move is clear.
No news headlines were found in the last 48 hours, so the 33% gain likely reflects either a technical bounce, a delayed market reaction to an earlier announcement, or an untracked catalyst such as a press release not yet indexed by Yahoo Finance.
The absence of recent headlines in the provided news feed makes it impossible to identify a specific catalyst for MODD's sharp 33% single-day rally. For a micro-cap medical device company trading at $2.45, such moves are not uncommon and can stem from several typical sources: a clinical trial result or FDA approval announcement not yet widely distributed, a partnership or contract win, short covering in a thinly traded security, or retail investor attention driven by social media or technical breakout patterns. Without access to company press releases, SEC filings, or broader financial news beyond the Yahoo RSS feed provided, the specific driver remains unknown. The ranking as the 10 biggest gainer suggests broad market awareness, but that does not establish causation.
No news headlines were found in the last 48 hours, so the 32.94% gain cannot be attributed to a disclosed catalyst; the move likely reflects technical trading, delayed news dissemination, or an undisclosed catalyst.
SXTC gained over 32 percent on August 14, 2026, but no news headlines appeared in the Yahoo Finance RSS feed during the preceding 48 hours. This absence of published information makes causal attribution difficult. For a small-cap pharmaceutical stock like SXTC, such large single-day moves can result from several categories of events: a clinical trial update or regulatory decision that may have been released outside of major news aggregators, short covering or technical buying following sustained weakness, sector rotation into biotech, analyst initiation or upgrade, insider activity becoming visible through market microstructure, or simply low trading volume amplifying minor order imbalances. Without access to press releases, filings, or internal trading data, pinpointing the specific driver is not possible from the evidence available.
No news headlines were found in the last 48 hours, so the 32% gain in HEPA stock likely stems from technical trading, retail momentum, or an undetected announcement outside the Yahoo Finance RSS feed.
Hepion Pharmaceuticals is a small-cap biotech stock trading at $0.08, and the absence of any news in the provided headlines makes attribution difficult. However, micro-cap and penny-stock biotechs are highly sensitive to several non-news catalysts: short covering (especially if the stock had elevated short interest), retail trading volume spikes or social media mentions, technical breakouts above key resistance levels, or delayed announcements that did not yet appear in mainstream financial news feeds. It is also possible that company-specific developments such as trial updates, partnership news, or regulatory filings were announced through channels other than Yahoo Finance's RSS service. Without access to those alternative sources or the stock's short interest data, we cannot pinpoint the driver with confidence.
AudioEye reported Q2 2026 earnings with 42 consecutive quarters of revenue growth, beat earnings estimates by 4.55%, and raised full-year adjusted EBITDA guidance to at least $12.7 million, driving the 31.56% gain.
The headline consensus is clear: AudioEye delivered a positive earnings surprise on August 13th after market close. The company reported Q2 2026 revenue of $10.7 million, up 9% year-over-year, and extended its streak of sequential revenue growth to 42 consecutive quarters, which is a significant milestone. Most importantly, management raised full-year adjusted EBITDA guidance to at least $12.7 million, described as a record. Although the company reported a GAAP net loss of $865,000 or 7 cents per share, the adjusted earnings beat expectations by 4.55% and revenues beat by 0.06%. The guidance raise is typically the strongest driver of post-earnings stock appreciation, as it signals management confidence in the forward outlook and often implies operational momentum that extends beyond the reported quarter.
No news headlines were available in the last 48 hours, so the 30.87% gain likely reflects either delayed market reaction to an untracked announcement, technical/sentiment-driven movement, or sector momentum in biotech.
Apollomics is a clinical-stage biopharmaceutical company, and the absence of any news in the Yahoo Finance RSS feed over the past two days makes it difficult to pinpoint a specific catalyst for the 30.87% jump. Biotech stocks of this profile typically move sharply on clinical trial results, FDA decisions, partnership announcements, or changes in development pipeline status. The magnitude and ranking of today's move suggests a material event rather than routine trading. Possibilities include a press release or announcement that has not yet propagated through standard news feeds, a delayed market reaction to recent company communications, short covering if the stock was heavily shorted, or sector-wide positive sentiment in oncology or immunotherapy spaces. Without corroborating headlines, any specific explanation remains speculative.
Stonegate Capital Partners updated coverage on NeOnc Technologies with commentary on meaningfully improved 2Q26 results, likely driving a 30.67% intraday surge in a small-cap healthcare stock.
The headline indicates that Stonegate Capital Partners, an equity research firm, published an updated analyst report on NeOnc Technologies covering second-quarter 2026 results. The phrase "meaningfully imp" (truncated in the source) most likely refers to "meaningfully improved" performance, which would be a positive catalyst. For a small-cap stock trading at $4.23, analyst upgrades or positive commentary on quarterly results can trigger strong single-day moves, particularly if the prior consensus was more skeptical or if the results beat expectations materially. The 15 ranking among daily gainers and the 30% move is consistent with the size and volatility profile of a micro-cap healthcare or biotech name. Without the full text of the Stonegate report, we cannot confirm whether this was a formal upgrade, a price target raise, or simply a newly initiated positive report, but the timing between the news timestamp and the price action aligns well.
No news headlines appeared in the last 48 hours, so the 30.65% surge cannot be attributed to a disclosed event. The move is likely driven by technical factors, retail trading activity, or undisclosed company developments not yet reflected in financial feeds.
Missfresh Limited experienced a significant single-day gain of over 30 percent with no corresponding news coverage in the Yahoo Finance RSS feed during the prior 48 hours. This disconnect between price action and reported headlines suggests the catalyst either arrived through channels not captured in standard financial news aggregators, emerged as intraday trading momentum, or involved speculation unmoored from new information. Missfresh is a Chinese online fresh grocery platform that has faced historical volatility and liquidity challenges typical of smaller-cap international stocks. Without specific structural intelligence about pending catalysts, reverse splits, or short squeeze dynamics, the most plausible explanations include technical rebound from oversold conditions, retail accumulation based on social media activity, options-driven gamma movements, or a company announcement distributed through non-standard channels that has not yet been indexed by major financial news services.
Evolution Metals appointed retired U.S. Air Force General Thomas A. Bussiere to its board, signaling potential defense-sector credibility and strategic positioning that likely drove the 30% intraday surge.
The headline announces a high-profile board appointment of a four-decade Air Force executive with experience in global strike command, defense logistics, and multi-billion-dollar enterprise leadership. For a small-cap metals and technology company trading at $3.01, such an appointment signals potential access to defense contracting opportunities, government relationships, and operational credibility in the defense-industrial space. Investors in micro-cap and small-cap stocks often respond sharply to leadership additions that suggest new revenue streams or strategic pivots, particularly when the appointee carries government and logistics authority. The timing of the announcement (Wednesday evening) coupled with the stock's ranking as the 17th biggest gainer on Thursday suggests this board news was the primary catalyst. However, the announcement does not specify any new contracts, partnerships, or business wins, so the move reflects investor optimism about future possibilities rather than a concrete near-term event.
Presurance Holdings reported second quarter 2026 financial results on August 12, likely driving the 28.66% jump as investors reacted to the earnings announcement on August 14.
The headline confirms that Presurance Holdings released its Q2 2026 financial results on August 12, 2026, covering the first half of the year ended June 30. The news item is truncated and does not provide specific metrics, earnings per share, revenue figures, margin changes, or management guidance that would explain investor enthusiasm. However, the timing strongly suggests the rally on August 14 correlates with the earnings release two days prior. The stock's substantial 28.66% single-day gain ranks it as the 18th biggest mover on the NASDAQ, indicating market-wide recognition of a material positive catalyst. Without access to the full earnings details, the specific driver—whether a revenue beat, profitability surprise, strategic announcement within the earnings, or forward guidance—remains unclear from the headline alone.
MDxHealth beat revenue estimates by 5.46% and reported record sequential growth in Q2 2026 while eliminating a $10.4 million liability, driving a nearly 28% single-day rally from a depressed stock price.
MDxHealth reported second quarter 2026 results on August 13 that included 16% year-over-year revenue growth to $27.2 million, beating consensus by 5.46%, along with what the company characterized as the largest quarter-over-quarter revenue acceleration in its history. Beyond the revenue beat, the elimination of a $10.4 million liability and improved balance sheet strength appear to have resonated positively. A net loss versus consensus estimates created a negative earnings surprise of 50%, yet the market has weighted the revenue acceleration, balance sheet strengthening, and sequential momentum more heavily. This price action is consistent with a turn in investor sentiment toward operational progress and financial health indicators after what may have been a period of underperformance or investor skepticism, particularly given the stock's sub-dollar starting price suggesting prior distress.
No news headlines appeared in the last 48 hours, so the 26.5% jump likely reflects either a delayed market reaction to an earlier announcement, a technical/short-covering event, or undisclosed clinical or commercial development at the biotech company.
VYNE Therapeutics is a dermatology-focused biotech with a small market cap, the type of stock prone to sharp moves on limited volume. The absence of news in the past 48 hours does not rule out a move driven by older announcements that only reached broader investor attention on August 14, or a short-squeeze if shares were heavily shorted. Alternatively, the gain could stem from internal developments not yet released to the public, such as positive trial data, partnership news, or regulatory feedback that insiders or select investors learned about ahead of a formal announcement. For a micro-cap biotech, clinical trial readouts, FDA feedback letters, and partnership announcements are the most common catalysts; contract wins or licensing deals are secondary drivers.
No news headlines were found in the last 48 hours, so the 26% intraday gain for Latch appears driven by technical factors, retail interest in a penny stock, or an undetected news event not captured in the Yahoo Finance RSS feed.
Latch trades at $0.19, placing it firmly in penny-stock territory where price movements can be volatile and driven by factors other than company fundamentals or major announcements. The absence of any news in the last 48 hours means the jump cannot be attributed to earnings, guidance, product launches, or strategic developments that would typically be captured in financial news feeds. For stocks trading at this price level and market cap, catalysts often include technical rebounds, short covering, retail social-media attention, or liquidity events that move the bid-ask spread sharply. It's also possible a material announcement exists but was not indexed by the RSS feed used here, or the move reflects delayed reaction to prior-week news.
No news headlines were found in the last 48 hours, so the 25.62% gain on TONT.WT cannot be directly attributed to a disclosed event. The move likely reflects technical trading, short covering, or undisclosed developments in a low-price warrant security.
Graf Global Corp warrant (TONT.WT) jumped 25.62% to $0.49 on August 14, 2026, but no news headlines were published in the prior 48 hours to explain the move. This absence of news in a major financial data feed suggests either the catalyst was not widely distributed through mainstream press, or the move is driven by factors other than a new announcement. Warrant securities, particularly those trading at low prices, are sensitive to technical trading patterns, short squeezes, and retail interest. Possible non-news drivers include renewed interest in the underlying TONT shares, changes in implied volatility, or movements in correlated assets. Without additional context about the company's fundamentals or recent corporate developments, attribution remains speculative.
TMCR surged 24.96% following the company's second quarter 2026 corporate update released on August 13, likely driven by positive operational or financial results communicated in that filing.
The headline indicates that TMC (the metals company) released a Q2 2026 corporate update on August 13, 2026, the day before this sharp 25% gain. The full text of the announcement is truncated in the provided excerpt, so the specific content—whether it covers production metrics, revenue growth, strategic partnerships, operational milestones, or changes to guidance—cannot be verified here. However, the timing correlation is strong: a major corporate update released after market close on the 13th would naturally drive trading on the 14th. For a metals royalty company, positive catalysts typically include increased production forecasts, new royalty agreements, higher commodity price realizations, or operational efficiency gains. Without the full text, we cannot confirm which factor drove the move, but the proximity of the announcement to the price action makes news-driven movement the primary hypothesis.
No news headlines were found in the last 48 hours, so the 24.80% gain cannot be tied to a specific announced catalyst; the move likely reflects technical buying, short covering, or delayed market reaction to an earlier event.
Creative Global Technology Holdings Limited Ordinary Shares jumped 24.80% on August 14, 2026, but no recent news headlines are available to explain the move. This creates a gap between the price action and any identifiable catalyst. For a NASDAQ-listed company, large single-day gains without accompanying headlines typically result from one of several mechanisms: short covering or squeeze dynamics if the stock has significant short interest, technical breakout triggering automated or momentum-based buying, delayed market reaction to news released outside the RSS feed window, or unconfirmed rumors or social media activity. Without access to intraday volume, short interest data, or broader market context, we cannot determine which mechanism drove this stock. The absence of earnings, guidance, M&A, or regulatory news in the headline feed does not rule out those events having occurred; it simply means they are not visible in the provided data sources.
Western Union and Intermex announced an update on regulatory approvals for the pending acquisition on August 14, likely signaling progress toward deal closure, which drove a 24.6% gain in IMXI stock.
The most direct catalyst is the August 14 joint announcement from Western Union and Intermex providing an update on regulatory approvals for the $500 million acquisition. While the headline excerpt does not detail the specific content of that update, the timing of the announcement on the same day as the +24.6% jump, combined with IMXI's status as the acquisition target, strongly suggests investors interpreted the update as positive news on deal progression. Prior reporting on August 12 noted headwinds including an 18% year-over-year revenue decline and competitive fintech pressure, which could have weighed on the stock independently. The regulatory update announcement overrode those concerns, indicating likely clearance or near-certainty of deal completion, which typically drives target stock appreciation toward the deal price.
DEFSEC announced third quarter fiscal 2026 results on August 13, likely driving the 23.59% jump as investors reacted positively to the earnings release the following trading day.
The only news headline provided is an earnings announcement from August 13, 2026, for DEFSEC's third quarter fiscal 2026 results. The headline text is truncated and does not include specific financial metrics, guidance changes, or other details that would normally explain a strong positive reaction. However, the timing is consistent: the announcement came after market close or during off-hours on August 13, and the stock jumped 23.6% on August 14, the next trading day. This pattern strongly suggests the market responded favorably to whatever was in those quarterly results. Without access to the actual earnings figures, margins, revenue growth, or forward guidance, I cannot identify which specific metrics or announcements drove the gain, but the magnitude of the move suggests either a significant earnings beat, positive guidance revision, or other material development disclosed in the earnings release.
Ideal Power reported Q2 2026 earnings on August 13 with positive highlights including solid-state circuit breaker progress, a $400M sales funnel expansion, and a $27.7M capital raise, driving a 23.53% single-day gain.
The stock moved sharply upward following the release of Ideal Power's Q2 2026 financial results and earnings call on August 13. The headlines consistently emphasize three constructive elements: advancement of the company's B-TRAN bidirectional semiconductor switch technology toward commercialization, particularly through a prototype program with a lead Asian customer; expansion of the commercial sales pipeline to $400 million; and completion of a $27.7 million capital raise to strengthen the balance sheet. For a pre-revenue or early-stage semiconductor developer, these milestones signal material progress toward revenue generation and reduced near-term financing risk. The timing of the announcement, the scale of the sales funnel, and the capital raise together appear sufficient to justify a substantial single-day move in a micro-cap equity trading at $5.25.
No news headlines were found in the last 48 hours, so the 22.61% gain on EXOD likely stems from technical momentum, retail attention, or an untracked corporate announcement rather than mainstream media coverage.
The absence of any Yahoo Finance headlines in the past two days makes it difficult to pinpoint a specific catalyst for the jump. EXODUS MOVEMENT INC. is a small-cap stock that may experience outsized moves on light volume or social media attention that doesn't immediately appear in major news feeds. Possible causes include a delayed press release not yet picked up by RSS aggregators, technical breakout attracting momentum traders, short covering if the stock carries significant short interest, or company-specific developments that haven't reached mainstream financial news yet. Without access to the company's investor relations channels or real-time social media tracking, we cannot confidently assign this move to any particular event.
CAMP4 Therapeutics reported Q2 earnings that beat both revenue and earnings estimates and secured regulatory clearance to initiate its first Phase 1/2 clinical trial for CMP-002, a treatment for a rare genetic disorder, driving the 22.6% gain.
The stock jumped on two linked positive catalysts reported on 2026-08-13. First, CAMP4 beat analyst expectations on both earnings (up 8.33%) and revenue (up 31.78%) for Q2 2026, which alone can justify a meaningful single-day move for a small-cap biotech. Second and more significant, the company secured regulatory clearance in two jurisdictions to initiate a Phase 1/2 clinical trial for CMP-002 in patients with SYNGAP-1 related disorder, with trial initiation anticipated in Q4 2026. For an early-stage biotech, regulatory approval to begin a first-in-human trial is a major milestone and de-risks the path to potential commercialization. The combination of quarterly performance beats plus clinical progress in a rare disease program with limited competition likely explains the sharp upward move.
TechPrecision reported Q1 2027 earnings showing 23% revenue growth and 36% gross profit growth, which likely drove the 21.86% stock jump as investors responded positively to the strong financial results.
The company released fiscal year 2027 first quarter financial results on August 13, with consolidated revenue and gross profit both posting double-digit gains at 23% and 36% respectively. The earnings call highlights published August 14 emphasize robust top-line growth and improved margins, which are fundamental metrics that equity investors typically reward. The headlines do acknowledge that Stadco turnaround efforts and liquidity remain focus areas, suggesting some underlying operational or financial concerns persist, yet the market's reaction indicates investors weighted the strong earnings results more heavily than these caveats. The timing aligns perfectly with the stock's intraday move, and the magnitude of the gain is consistent with positive earnings surprises in small-cap industrials.
RCM Technologies surged 21.84% following a strong Q2 2026 earnings beat with earnings up 51.85% and revenues up 16.30% versus estimates, combined with bullish Wall Street analyst sentiment rated Buy.
RCM Technologies released second quarter 2026 results on August 13–14, 2026, delivering a significant earnings surprise of +51.85% and a revenue surprise of +16.30% relative to consensus estimates. These beats represent material operational outperformance and typically drive substantial single-day rallies in mid-cap stocks. The timing aligns precisely with the 21.84% one-day gain. Additionally, the news flow includes commentary that Wall Street analysts hold an average Buy rating on the stock, suggesting institutional research support for the company's strategic direction. The combination of quantified earnings upside, revenue growth acceleration, and positive analyst positioning creates a multi-factor catalyst. The prior day's close at $28.92 implies a jump to approximately $35.23 today, consistent with the reported $35.03 price, confirming the earnings announcement as the primary driver.
Inovio reported narrowed net losses and FDA progress on its lead candidate INO-3107 in Q2 earnings on August 13, plus secured funding through late Q1 2027, triggering a 21.6% jump as investors responded positively to clinical and financial momentum.
The stock's strong gain aligns directly with Inovio's Q2 2026 earnings announcement on August 13. The company reported a narrowed net loss, demonstrating improved financial discipline, and disclosed that the FDA has completed several key steps in reviewing its biologics license application for INO-3107, an investigational treatment for HPV-related diseases and cancer. The company also announced it had secured sufficient funding to operate through late Q1 2027, removing near-term cash runway concerns that typically weigh on biotech valuations. For a pre-revenue biotech company, FDA progress on a lead asset combined with financial stability is a material positive catalyst. The timing of multiple headlines within 48 hours all covering the same earnings event suggests broad analyst coverage of what appears to be a meaningful inflection point in the company's development timeline.
No news headlines were found in the last 48 hours, so the 21.57% gain likely stems from technical trading activity, short covering, or a delayed market reaction to an earlier announcement not captured in the search results.
The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for BBBY.WT's strong 21.57% intraday gain. BBBY.WT is a warrant on Bed Bath & Beyond common stock, which makes it a leveraged instrument sensitive to moves in the underlying equity. Warrants can exhibit outsized percentage swings relative to the stock itself due to their structural leverage and lower absolute price levels. Without news, the most likely candidates are technical factors such as short covering if the warrant had been heavily shorted, a momentum-driven rally in the broader retail sector, or a delayed market reaction to news that occurred before the 48-hour window. Alternatively, there could be an unannounced company development, trading algorithm activity, or shift in implied volatility expectations, but these remain speculative.
Angel Studios reported a 99% surge in Guild membership and reaffirmed its path to profitability with capped full-year adjusted EBITDA losses, likely driving the 21% gain as investors responded positively to the strong user growth and improved financial trajectory.
The earnings call highlights released on 2026-08-13 show two material positives: a dramatic 99% increase in Guild membership, indicating strong user acquisition and engagement momentum, and management's reaffirmation of a path to profitability with adjusted EBITDA losses capped at $25 million for the full year. For a smaller-cap entertainment platform company like Angel Studios, membership growth at that scale is a key metric investors watch as a leading indicator of future monetization potential and unit economics improvement. The explicit cap on losses combined with the membership surge suggests the company is demonstrating both growth and financial discipline, which could have catalyzed buying pressure particularly among growth-focused or value-oriented investors who saw previous concerns about path to profitability being addressed.
Net Power reported Q2 2026 results on August 13 and announced a strategic shift toward behind-the-meter natural gas generation for data centers, which likely drove the 20.86% gain as investors responded positively to the refocused business strategy.
Net Power released second quarter 2026 earnings results and provided a business update on August 13, followed by an earnings call on August 14. The key catalyst appears to be management's announcement that the company is redirecting its near-term development strategy toward unabated, behind-the-meter natural gas generation, driven by prospective customer demand for rapid access to reliable power for data centers. This strategic pivot signals a more near-term revenue opportunity and addresses actual market demand. The timing and magnitude of the gain on the day of the earnings call suggests investors viewed this repositioning as positive, potentially because it offers a clearer path to monetization than prior strategy or because data center demand is perceived as more robust and certain than alternative markets the company may have been targeting.
No news headlines were found in the last 48 hours, so the 20.73% gain likely reflects either a delayed market reaction to an earlier announcement, technical trading activity, or an untracked catalyst such as a press release or regulatory development.
The absence of any recent news headlines within the 48-hour window makes direct causal attribution impossible from the provided evidence. BioSig Technologies is a small-cap biomedical device company, and stocks in this category can be sensitive to clinical trial updates, regulatory submissions, partnership announcements, or even technical momentum and short covering. The magnitude of the move (36th largest gainer of the day) suggests something material occurred, but without access to news sources beyond the Yahoo Finance RSS feed provided, the specific trigger cannot be identified. Possible categories of catalyst include a positive clinical or regulatory development, institutional buying, short squeeze dynamics, or a market-wide rerating of small-cap biotech. Without headlines, none of these can be confirmed.
No news headlines were found in the last 48 hours for BSGM, so the 20% intraday gain likely stems from technical factors, delayed coverage of an earlier announcement, or sector-wide momentum in small-cap biotech.
BioSig Technologies is a micro-cap biotech firm trading at $1.04, and a 20% single-day jump with zero recent news coverage is atypical of fundamentally driven moves. The absence of headlines does not rule out a catalyst, however. Possibilities include a delayed market reaction to an announcement made more than 48 hours ago (regulatory approval, partnership, clinical data), short-squeeze activity common in illiquid small-cap stocks, or broad sector strength in cardiac diagnostic or medical device companies. Micro-cap stocks often exhibit outsized volatility on low volume and limited float, so technical breakouts or retail interest can amplify single-day moves independent of fresh news. Without contemporaneous headlines, the specific driver remains unidentifiable.
No news headlines were published in the last 48 hours for VINE, so the 19.85% gain on August 14 cannot be attributed to a reported catalyst. The move likely reflects technical trading, retail momentum, or an unreported development.
Fresh Vine Wine is a micro-cap stock trading at $0.25 with minimal liquidity and analyst coverage typical of stocks at this price level. The absence of any news in the last 48 hours means the jump cannot be tied to earnings, guidance, strategic announcements, or industry events that would normally drive meaningful moves. At this capitalization and price point, gains of this magnitude are often driven by technical factors such as short covering, thin-float momentum trading, options activity, or social media chatter among retail traders rather than fundamental business developments. Without access to intraday volume data, option flow, or social media sentiment, the specific catalyst remains unidentifiable.
No news headlines were found in the last 48 hours, so the 19.62% gain in this penny stock warrant likely reflects technical trading, a delayed announcement, or retail momentum rather than any identifiable fundamental catalyst.
PEW.WT is a warrant on GrabAGun Digital Holdings, a micro-cap security that can exhibit outsized price swings on low volume with minimal news flow. The absence of any headlines in the Yahoo Finance RSS feed over the past two days means we cannot point to an earnings surprise, regulatory action, partnership, or guidance change. Warrants are inherently leveraged instruments and often see volatile trading driven by technical factors, options positioning, short covering, or retail interest rather than fundamental news. Without access to the underlying stock's performance, option activity, or insider filings on the snapshot date, the most honest assessment is that this move may reflect trading mechanics, a delayed press release not yet syndicated to major feeds, or organic retail attention to a highly speculative instrument.
No news headlines were found in the last 48 hours for PROP, so the 19.54% intraday gain cannot be attributed to a confirmed catalyst. The jump likely reflects technical trading, retail attention, or an unannounced development not yet picked up by major news feeds.
With no headlines identified in the search window, we cannot point to a specific company announcement, earnings release, contract win, or regulatory decision to explain the move. PROP is a small-cap petroleum exploration and production company trading at $1.01, which historically makes such stocks sensitive to several catalyst types: crude oil price swings, short-covering rallies, insider activity, rumors on social media or message boards, or delayed news not yet indexed by RSS feeds. The 19.54% gain is substantial enough to suggest more than random noise, but without corroborating news, we must acknowledge that the true driver remains unknown. It is possible an announcement was made outside normal news channels or will appear on the company's investor relations website before being picked up by financial media.
No news headlines were found in the last 48 hours to explain the 19.44% gain in CELG.RI, so the driver remains unclear without additional information about market events or company announcements.
The absence of recent news makes it difficult to pinpoint a specific catalyst for this 19.44% jump on August 14, 2026. CELG.RI, a Bristol-Myers Squibb subsidiary or rights offering related to its Celgene division, could have moved on several possible grounds: a delayed announcement not yet reflected in the Yahoo Finance RSS feed, technical or short-covering activity in a thinly traded security, or broader pharmaceutical sector sentiment. Without headline evidence, we cannot determine whether the move reflects genuine company news, a sector rotation, or purely technical trading. The stock's low price of $0.11 and appearance as a top gainer suggests moderate absolute volume may have generated outsized percentage moves, but this remains speculative without order flow data.
No news headlines were found in the last 48 hours to explain ZSTK's 19.39% jump on August 14, 2026, so the catalyst remains unknown.
Zero news items appeared in the available Yahoo Finance RSS feed over the last two days, which is unusual for a stock gaining nearly 20% and ranking in the top 50 movers. This absence of reported news does not mean no catalyst exists; it may indicate the move was driven by technical trading, an unindexed announcement, delayed financial results, a short squeeze, options expiration effects, sector rotation, or rumors not yet captured by major news outlets. Without additional information about ZeroStack Corp.'s business model, market cap, float, or recent trading patterns, it is not possible to narrow the likely cause further. The stock trades at $1.92, suggesting it may be a micro-cap or turnaround situation, which typically sees higher volatility and larger single-day moves on thin news.
No news headlines were available in the last 48 hours, so the 19.37% gain cannot be directly attributed to a specific announcement. The jump likely reflects either delayed market reaction to an earlier announcement, technical trading, or sector rotation in gaming/gambling stocks.
The absence of recent headlines makes it impossible to pinpoint a concrete catalyst for GAMB's 19.37% single-day jump. Gambling and online gaming stocks can be sensitive to regulatory developments, sports betting trends, quarterly earnings surprises, or shifts in consumer sentiment around gaming. Without headline evidence, the move could reflect a delayed market response to news that broke before the 48-hour window, algorithmic or momentum trading in a smaller-cap stock, short covering if the name carries significant short interest, or rotation into the gaming sector based on macro factors or competitor announcements not yet captured in the news feed. Without additional data, these remain speculative categories rather than confirmed causes.
No news headlines were found in the last 48 hours for Myomo Inc, so the 19.11% gain cannot be directly attributed to a specific announced catalyst. The move may reflect technical trading, delayed market reaction to earlier news, or company-specific developments not yet covered by major news feeds.
Myomo is a medical robotics company focused on powered orthotic devices, a sector that typically responds to clinical trial results, FDA clearances, reimbursement decisions, partnership announcements, or changes in competitive positioning. The absence of recent headlines in the Yahoo Finance RSS feed does not mean no catalyst exists—it may indicate that relevant news was published through other channels, appeared outside the 48-hour window, or that market participants are reacting to internal developments or technical factors. For a micro-cap stock trading below $2, intraday volatility and low-volume momentum moves are common. The stock could also be responding to positive developments in the broader medical device or rehabilitation robotics sector, or to short-covering activity if significant short interest exists.
Expion360's Q2 earnings showed a net loss per share that narrowed year-over-year despite a 32% revenue decline, driven by improved gross margins to 32.4% from a strategic product mix shift away from low-margin offerings, prompting an 18.93% stock price jump.
The company reported Q2 results on August 13 that demonstrate operational leverage through margin expansion rather than top-line growth. The headline specifically notes that net loss per share improved year-over-year, which is a meaningful metric for investors assessing whether the company is moving toward profitability. The gross margin expansion to 32.4% signals that management's deliberate shift to higher-margin products is working, even though total sales contracted sharply. This is a classic turnaround narrative: sacrificing near-term revenue to improve unit economics and path to profitability. For a stock trading at $3.66, this kind of evidence of improving fundamentals and strategic repositioning can trigger significant short-covering or renewed retail interest. The 18% gain appears proportional to the positive signal contained in the earnings release.
No news headlines were available in the last 48 hours to explain the +18.87% gain in FEED stock, so the catalyst remains unclear without additional information about company announcements or market-wide events.
The absence of recent news headlines makes it difficult to pinpoint a specific cause for the move. Micro-cap medical device stocks like ENvue Medical can experience volatile intraday swings from several categories of unlisted catalysts: delayed earnings or clinical trial results posted after market hours, insider trading activity that precedes public announcements, short-covering in a thinly traded security, technical oversold conditions on a stock trading at $0.46 per share, or sector-wide enthusiasm from healthcare or medtech news unrelated to this specific company. The substantial gain at rank 46 of daily gainers suggests this was a genuine market-driven move rather than pure noise, but without corroborating headlines or press releases, we cannot distinguish between these possibilities. The stock's low price point and likely low trading volume typical of penny-cap stocks make it susceptible to larger percentage swings on smaller absolute dollar volume, which complicates attribution.
No headlines were found in the last 48 hours to explain YDES's 18.73% gain, so the specific catalyst remains unknown; the move could reflect delayed news coverage, technical factors, or sector-wide momentum in biotech stocks.
YD Bio Limited (YDES) jumped 18.73% on August 14, 2026, but no recent news headlines were available to identify a concrete trigger. This absence of reported news within the 48-hour window does not rule out a catalyst—it may simply indicate a lag in headline indexing, an announcement made outside major wire services, or a delayed market reaction to older information. Biotech stocks, particularly smaller-cap names trading at $3.11, are sensitive to clinical trial results, regulatory decisions (FDA pathway clarity, trial approvals), partnership announcements, or changes in funding outlook. Without access to the company's press releases, SEC filings, or specialized biotech news sources, we cannot determine whether this was driven by company-specific developments, a broader biotech sector rally, short covering, or technical momentum. The stock's rank as the 47th biggest gainer suggests material sector interest that day, but that alone does not isolate the cause.
No news headlines were found in the last 48 hours, so the 18.61% gain likely stems from technical trading activity, a delayed market reaction to older news, or an untracked announcement outside the RSS feed examined.
The absence of recent headlines despite a strong single-day gain of 18.61% makes it difficult to identify a specific catalyst. For small-cap biotech stocks like CytoMed Therapeutics, typical drivers of sharp moves include clinical trial results, regulatory approvals or communications, partnership announcements, or insider transactions. The stock's low price of $0.95 and modest market rank suggest it may be subject to higher volatility and technical trading patterns. Without corroborating news in the provided sources, the move could reflect a short squeeze, algorithmic accumulation, options expiration effects, or a company announcement that has not yet been indexed by the news aggregator. The possibility of a delayed market response to older developments also cannot be ruled out.
No news headlines were found in the last 48 hours, so the 18.5% gain on this warrant cannot be directly attributed to a disclosed catalyst. The move may reflect technical trading, short covering, or delayed market reaction to untracked news.
EON Resources Inc WT is a warrant security, which tends to exhibit higher volatility than the underlying common stock due to leverage and shorter duration. Without any headlines from Yahoo Finance in the last 48 hours, there is no disclosed event such as an earnings report, regulatory approval, or business announcement to anchor the move. Warrant price moves of this magnitude often reflect either technical factors (e.g., a breakout triggering momentum trading), short squeeze dynamics if the warrant is heavily shorted, or market reaction to news that did not appear in the RSS feed provided. Penny-weight securities like warrants at $0.09 are also more susceptible to low-volume spikes and retail interest shifts. Without concrete information, the specific driver remains unknown.
No news headlines were found in the last 48 hours, so the 18.48% gain on NSPR likely reflects technical trading activity, a delayed market reaction to an older announcement, or sector-wide movement in small-cap medical device stocks.
InspireMD is a micro-cap medical device company, and the absence of any news in the last 48 hours means the move cannot be anchored to a recent earnings release, FDA approval, contract announcement, or guidance change. For stocks at this market capitalization and price point, significant single-day moves often reflect technical factors such as short covering, options expiration effects, or momentum trading by retail investors responding to price action rather than fundamental catalysts. It is also possible that a press release was issued but not yet indexed by the RSS feed, or that the move is a delayed reaction to news from earlier in the week. Without access to the company's recent SEC filings, insider trading activity, or social media discussion, a specific cause cannot be determined.
Biggest Losers
50No news headlines were reported in the last 48 hours, but a 97.73% collapse in a SPAC suggests either a failed merger deal, shareholder vote rejection, or major redemption event that triggered delisting or liquidation risk.
HCM Acquisition Corp is a special purpose acquisition company (SPAC) that trades on the basis of merger completion probability and timeline. A near-total wipeout of 97.73% in a single day with zero news coverage in the prior 48 hours points to a structural event rather than gradual deterioration. The most likely causes fall into two categories: (1) a scheduled shareholder vote to approve a merger or extend the SPAC's deadline failed or was postponed, triggering automatic liquidation provisions or shareholder redemptions that collapsed the trust value, or (2) an adverse announcement about deal status or sponsor confidence that hit after the news cutoff. SPACs that enter their final liquidation window or face shareholder redemption waves often experience exactly this kind of cliff-edge price action. Without confirming headlines, we cannot establish which specific event occurred, but the magnitude and suddenness are characteristic of SPAC structural failure rather than business deterioration.
No news headlines were found in the last 48 hours, so the 73% drop cannot be attributed to a disclosed event. This magnitude of loss in a SPAC typically reflects either a deal collapse, failed merger conditions, or a major adverse development that has not yet appeared in public headlines.
Armada Acquisition Corp. I is a blank-check company, and a 73% single-day collapse of this magnitude is extreme. Without any news in the provided headlines, the catalyst remains unidentified in publicly available reporting at the snapshot time. For SPACs, such severe moves commonly follow failed merger negotiations, investor redemptions tied to deal terms, regulatory rejection of a proposed combination, or management departures. The lack of any disclosed news within 48 hours of this massive move suggests either a very recent development that has not yet propagated to major news feeds, a private communication to shareholders, or a market reaction to anticipated news. Given the stock price of $2.67, this is already near the redemption floor for many SPAC structures, which itself may reflect prior deterioration in deal viability.
AmpliTech reported strong Q2 earnings with 51% sequential revenue growth and 161% gross profit growth year-over-year, but the AMPGZ Series B rights certificate may have experienced a sharp selloff due to dilution concerns or a change in the underlying common stock (AMPG) valuation following the e…
The headlines show that parent company AmpliTech Group reported robust second-quarter results on August 13, with revenue of $8.1 million up 51% sequentially and gross margin expanding dramatically to 27.9% from 7.8% year-over-year. These are operationally positive metrics. However, AMPGZ is a Series B rights certificate, not the common stock itself, and such securities are highly sensitive to changes in the underlying stock's valuation and market perception. The 69% single-day drop suggests either (a) a sharp repricing of AMPG common stock following the earnings announcement that proportionally hit the rights, (b) investor concern about dilution from the rights exercise, or (c) a technical/forced liquidation event specific to this illiquid derivative security. The earnings themselves appear solid on paper, but investor reaction to valuation, guidance, or balance sheet details mentioned during the earnings call is not detailed in the snippets provided.
OMI dropped 66% with no news in the last 48 hours, suggesting a catalyst outside the provided headlines—likely an earnings miss, guidance cut, or material corporate announcement released before the snapshot window.
Owens & Minor is a healthcare distribution and logistics company. A 66% single-day decline is severe and typically requires a major negative catalyst such as disappointing quarterly earnings, a dramatic downward guidance revision, loss of a major customer contract, or significant debt or covenant concerns. The absence of headlines in the last 48 hours does not mean no news was released; it may indicate the announcement came more than 48 hours prior, or the RSS feed simply did not capture it. Given OMI's business model sensitivity to healthcare spending and supply chain disruptions, potential triggers could also include competitive pressure, margin compression, or operational challenges. Without confirming headlines, the specific cause remains unclear, though the magnitude of decline rules out routine market volatility or technical factors alone.
No news headlines were found in the last 48 hours to explain the 64.92% drop in WINVR, which ranks as the fifth-biggest loser today. The collapse likely reflects a structural or market-wide trigger affecting SPACs or blank-check companies.
WinVest Acquisition Corp. is a SPAC (special purpose acquisition company), a security class prone to sharp moves on limited or no news when market conditions shift or investor appetite for blank-check vehicles deteriorates. The absence of any news in the provided 48-hour window suggests the move was not driven by company-specific headlines such as earnings, deal announcements, or guidance changes. Common catalysts for SPAC declines include broad redemption pressure ahead of a merger deadline, failed merger negotiations, deterioration in the target company's business fundamentals (if a deal was publicly known), or a sector-wide rotation away from unprofitable growth vehicles. Without access to news, we cannot determine which of these or other structural events triggered the collapse, though the magnitude and ranking suggest either a major deal failure, insider developments, or contagion from similar securities.
Innventure reported Q2 revenue of $1 million, missing analyst estimates by 51.62% and falling sequentially from Q1, triggering a 55% stock collapse and analyst price target cuts.
Innventure released second-quarter 2026 results on August 13 that fell sharply short of expectations. Q2 revenue came in at $1 million versus estimates around $2.06 million, a miss of over 51 percent. More concerning, revenue declined sequentially from $1.4 million in Q1 despite being up year-over-year from $500,000 in Q2 2025. The company's Accelsius cooling technology business represented 96 percent of revenue, indicating concentration risk. The earnings miss was accompanied by a loss and analyst downgrades on the same day. The sell-off intensified on August 14 when Yahoo Finance highlighted the weakness alongside York Space Systems experiencing similar declines, amplifying negative sentiment around high-risk growth stocks missing guidance. For an early-stage industrial technology company, revenue misses of this magnitude and direction typically signal execution challenges or slower-than-expected customer adoption.
Blaize slashed its 2026 revenue guidance by over 65% on August 13, cutting the outlook from $130 million to $40-43 million due to delayed customer deployments and failed conversions, triggering the 49.5% stock collapse.
The earnings report and earnings call on August 13 disclosed a severe miss. Blaize reported Q2 revenue that underperformed estimates by 4.71% and posted a net loss, but the headline driver was the dramatic guidance cut. Management cited delayed customer deployments and commercial opportunities that failed to convert as expected. While the company does project strong 2027 growth backed by a $50 million backlog, the near-term outlook collapse and evidence of execution risk have crushed investor confidence. A 65% revenue guidance reduction is a substantial negative shock that typically triggers sharp repricing, especially in a pre-profitable AI computing company where near-term growth expectations are critical to valuation.
KinderCare missed Q2 earnings estimates by 20% while revenue was essentially flat year-over-year, with enrollment pressure and center closures cited as headwinds, triggering a 46% single-day selloff.
KinderCare reported Q2 2026 results on August 13-14, revealing an earnings surprise of -20%, meaning actual EPS fell significantly short of analyst expectations. Revenue of $698 million showed essentially no growth compared to $700 million in the prior year quarter. The earnings call highlights specifically cited enrollment pressure and center closures as offsetting factors, suggesting operational deterioration in the core business. A 20% earnings miss on flat revenue is a material disappointment for a company in a capital-intensive childcare industry where operating leverage matters. The market's reaction of a 46% one-day decline reflects severe repricing of the stock, likely driven by concerns about future earnings trajectory, margin compression from underutilized capacity, and questions about management's ability to stabilize enrollment.
MicroVision announced a $17 million public offering on August 14, which typically dilutes existing shareholders and triggered a sharp 41% sell-off, likely driven by dilution concerns and possible insider selling pressure associated with the offering.
MicroVision announced the launch of a proposed public offering on August 13 and priced it at $17.0 million on August 14. Public offerings of this magnitude announced in rapid succession often signal equity dilution that depresses share price, particularly for smaller-cap companies where the proportional impact on the shareholder base is material. The timing of the pricing announcement coinciding with the largest single-day drop suggests market participants reacted negatively to the dilution, possible lock-up or insider selling windows opening, or concerns about the company's cash position necessitating the raise. No other material news about business fundamentals, contracts, or strategic developments is present in the headlines to offset this headwind.
No news headlines were published in the last 48 hours for GIPR, so the 40.83% drop cannot be attributed to a specific disclosed event; this magnitude of loss typically reflects either delayed market reaction to prior announcements, technical selling, or undisclosed fundamental concerns.
The absence of any news in the 48-hour window preceding this severe decline presents a challenge to attribution. Generation Income Properties is a real estate income company, and stocks in this sector are sensitive to interest rate expectations, dividend sustainability concerns, and credit market conditions. A 40.83% single-day loss without accompanying headlines suggests either that (1) negative information was released outside the Yahoo Finance RSS feed or on trading halts, (2) the market is repricing the company based on deteriorating sector conditions or macro factors not captured in news aggregators, or (3) a significant operational or financial issue emerged that has not yet been formally disclosed. This type of stock typically moves on distribution cuts, covenant violations, refinancing challenges, or material asset write-downs.
Akanda fell 38% despite announcing fiber network completion and revenue growth at its telecom subsidiary, suggesting the market either expected larger results, faced a separate negative catalyst, or reacted to guidance/timing issues not detailed in the headline.
The only headline provided announces a positive development: completion of a 200 KM fiber network and increased recurring revenue for Akanda's First Towers & Fiber subsidiary. On its surface this should be neutral to positive for the stock. However, a 38% single-day collapse is rarely explained by good news alone. The headline text is truncated and does not include full details on revenue figures, growth rates, profitability, or management guidance. Possible explanations include: (1) the full release contained disappointing forward guidance or margin pressure that the headline omits, (2) the market had expected much larger fiber deployment or revenue acceleration and viewed this as underwhelming, (3) a separate negative catalyst unrelated to telecom operations occurred simultaneously (financing dilution, executive departure, debt covenant issue), or (4) the announcement timing coincided with broader telecom sector weakness or a market-wide selloff on August 13-14, 2026.
CXApp announced a reverse stock split effective August 18, which typically signals financial distress or delisting risk; despite strong Q2 earnings (79% revenue growth), the split announcement drove the 35% intraday decline.
The company released strong earnings on August 13 showing 79% sequential revenue growth, $11.5 million ARR, and a path to breakeven by 2027 after acquiring EngineRoom. However, on August 14 morning the company announced a reverse stock split, with adjusted trading to begin August 18. Reverse splits are commonly implemented when a stock trades below regulatory minimums (NASDAQ requires stocks above $1 for sustained periods) or to improve optics ahead of financing. The market typically interprets reverse splits as a negative signal of financial weakness, even when accompanied by positive earnings, because they dilute shareholder value and signal potential delisting concerns. The timing—announcing the split the day after strong earnings—suggests the company may be preemptively addressing compliance issues rather than hiding bad news, but investor sentiment clearly weighed the split announcement more heavily than the earnings beat.
Gaxos announced a warrant exercise bringing in $3.6M in gross proceeds on the same day the stock fell 34%, likely triggering shareholder dilution concerns despite strong Q2 revenue growth of 1,337% year-over-year reported two days prior.
The company released two pieces of news within 48 hours: record Q2 revenue up 1,337% year-over-year on August 12, which would normally be bullish, followed by a warrant exercise announcement on August 14 that raised $3.6M in gross proceeds. The timing and magnitude of the 34% drop suggest the warrant announcement was the primary catalyst. Warrant exercises represent dilution to existing shareholders and may signal management views the stock as overvalued or that the company needed near-term capital despite strong revenue growth. The lack of any negative operational news or guidance revision makes the dilutive capital raise the most plausible explanation for the sharp sell-off. Investors often react negatively to equity issuances regardless of underlying business strength, especially when they appear opportunistic after a revenue beat.
No news headlines were found in the last 48 hours, so the 33.54% drop cannot be attributed to a disclosed event. The cause remains unknown but may reflect a delayed market reaction, earnings or guidance miss, or a rumor not yet indexed by major news feeds.
OFA Group experienced one of the day's largest declines with zero corresponding news coverage in the last 48 hours according to available sources. This disconnect suggests either a delayed reaction to older information, an unconfirmed rumor or social media catalyst, a technical breakdown in a thinly traded stock, or an internal corporate action not yet widely reported. Micro-cap and small-cap NASDAQ stocks like OFAL (trading at $1.07) often experience outsized moves on limited volume and can be sensitive to sentiment shifts, short squeezes, or private communications that precede formal press releases. Without a headline trigger, the most likely scenarios are an earnings disappointment, negative guidance revision, management change, or undisclosed liability that trades ahead of formal announcement.
Super League reported strong Q2 earnings with 16% sequential revenue growth and expanding margins, but the market sold off sharply anyway, suggesting investors either expected even better results, have concerns about forward guidance not mentioned in headlines, or are reacting to broader market o…
The news headlines describe materially positive Q2 2026 results: net revenue increased 16% sequentially, gross margin expanded five percentage points to 41%, and adjusted EBITDA improved approximately 20% year-over-year while maintaining cost discipline. On the surface, these are solid operational metrics that would typically support a stock price. However, a 33% single-day drop despite positive earnings indicates either a significant miss relative to consensus expectations, disappointing forward guidance, or a negative revelation during the earnings call itself that is not fully captured in the summary headlines provided. It is also possible the market is repricing the stock on structural concerns about the gaming or esports sector broadly, or that liquidity issues in a lower-priced micro-cap created outsized selling pressure.
Dare Bioscience announced a $6 million at-the-market registered direct offering on the same day as strong Q2 earnings and commercial progress, likely triggering a 32% sell-off due to shareholder dilution concerns despite positive operational results.
On August 14, Dare announced a $6 million registered direct offering priced at-the-market under Nasdaq rules. This occurred the day after the company reported strong Q2 results including a 1,775% revenue beat, launch of its first directly commercialized product (Flora Sync LF5), and progress on DARE to PLAY sildenafil cream toward Q3 revenue. While the earnings and product milestones are operationally positive, equity capital raises at distressed prices (the stock was already trading below $1.40 before the offering) are typically punished by markets as they dilute existing shareholders. The timing—announcing the offering same-day as earnings—may have magnified negative sentiment. Biotech stocks, particularly pre-profitability companies with low share prices, are especially sensitive to dilution announcements regardless of fundamental progress.
HCTI fell 30% despite reporting a 322% gross profit increase and 158% revenue growth for Q2 2026, suggesting the market either expected stronger results, has concerns about sustainability, or was already pricing in the gains before the announcement.
The stock dropped sharply on a day when the company announced exceptional financial results: Q2 2026 gross profit jumped 322% and revenue grew 158%. A separate analyst note mentions the company is "showing tangible evidence" of a successful transformation strategy. This disconnect between strong headline numbers and a severe sell-off is notable. Possible explanations include: first, the market may have already priced in these improvements ahead of the formal announcement, making the release a "sell the news" event despite good numbers. Second, investors may question the sustainability of such dramatic growth rates or fear they reflect one-time items rather than durable business improvement. Third, there could be concerns about margins, guidance, or other metrics not highlighted in the headlines provided. Without access to the full earnings report, guidance commentary, or balance sheet details, we cannot rule out negative context hidden in the earnings call.
Dawson Geophysical reported second quarter 2026 results on August 13, likely disappointing the market, triggering a 29.3% single-day sell-off in this small-cap geophysical services stock.
The only news provided is an announcement that Dawson Geophysical reported unaudited Q2 2026 financial results on August 13 at 20:05 UTC, with the stock falling sharply the following trading day. The headline does not disclose whether earnings beat or missed expectations, whether revenue grew or contracted, whether the company issued guidance, or what management commentary accompanied the results. For a small-cap industrial services company in the geophysical sector, negative surprises on profitability, backlog, pricing, or forward guidance would typically trigger sharp sell-offs. The 29% decline suggests a material negative disclosure, but the specific nature cannot be determined from the headline alone. Without access to the actual earnings release or analyst consensus estimates, attribution remains educated inference rather than confirmed fact.
No news headlines were found in the last 48 hours, so the 27.81% drop cannot be directly attributed to a public announcement. The decline may reflect technical selling, delayed reaction to an earlier event, or market-specific pressure on the stock.
Despite a significant single-day loss ranking ONFO as the 19th biggest loser on NASDAQ, no recent news headlines are available to explain the move. This absence of reported catalysts suggests the decline may be driven by technical factors such as stop-loss orders, momentum selling, or algorithmic trading pressure. It is also possible the market is reacting to news not yet captured in the RSS feed, or that a material development (earnings miss, insider selling, sector rotation, or executive changes) occurred but has not yet been widely reported. Without headlines or structural information about Onfolio Holdings, attribution remains speculative.
No news headlines were found in the last 48 hours for RMCF, so the 26.51% single-day decline lacks an obvious public catalyst and is most likely attributable to technical selling, broad market weakness, or undisclosed company developments.
The absence of any recent news makes it impossible to attribute the sharp drop to a specific announced event such as earnings miss, guidance cut, or operational problem. Rocky Mountain Chocolate Factory is a small-cap consumer discretionary stock, and such stocks are sensitive to several invisible forces: technical rebalancing, sector rotation out of consumer stocks, quiet insider selling, quiet analyst downgrades posted outside RSS feeds, or broader liquidity events affecting small equities. It is also possible that an announcement was made but not yet indexed by Yahoo Finance, or that material information was shared via a direct channel (company website, SEC filing) before news wires picked it up. Without contemporaneous headlines or structural context, the specific trigger remains unknown.
SoundThinking reported Q2 revenue below expectations and slashed full-year guidance by roughly 9 percent, citing deployment delays and slower sales cycles, triggering the sharp decline.
The headlines establish a clear earnings miss and material guidance cut. SoundThinking reported Q2 revenue of $23.9 million versus $25.9 million in the prior year, missing consensus by 7.71 percent. More significantly, management lowered full-year 2026 revenue guidance from a range of $109-111 million to $99-100 million, a reduction of approximately $10 million at the midpoint. The company cited elongated sales cycles, delayed deployments, and slower project timing. An earnings surprise of negative 37 percent on a per-share basis compounds the concern. For a smaller-cap industrial software company, a combination of topline contraction, forward guidance reduction, and operational headwinds typically triggers sharp repricing, particularly if investors had been positioned for growth or if analyst consensus had not baked in this magnitude of weakness.
Intellicheck reported Q2 earnings that matched estimates but revealed a major customer is undergoing a vendor-resiliency review that management warned could pressure transaction volumes and full-year results, triggering the 25% sell-off.
The company delivered Q2 revenue of $5.9 million (beating estimates by 3.14%) and modest net income of $633,000 (matching earnings expectations), which on the surface appears acceptable. However, the earnings call highlights disclosed a material forward-looking concern: a major customer's vendor-resiliency review poses a risk to transaction volumes and full-year guidance. This forward guidance warning likely dominated investor sentiment despite the beat on trailing metrics. For a small-cap identity validation company with limited diversification, loss or reduction of a major customer represents substantial downside risk. The market appears to have repriced the stock based on the visibility into this near-term headwind rather than the quarterly results themselves, which is a rational response to material uncertainty about customer retention.
OBAI dropped 22.7% on the same day it reported Q2 2026 results showing narrowed net losses and declining operating expenses, suggesting investors may have reacted negatively to either the absolute earnings figure, guidance, or dilution concerns despite operational improvements.
The company released a business update and second quarter financial results on 2026-08-14, highlighting positive operational metrics: net loss narrowed 28% year-over-year and operating expenses declined. The headline also mentions strong interest from cities in purchasing Bond for residents and city workers, plus demonstrated ability to fund growth while being sensitive to dilution. However, the headline is truncated and does not provide the actual net loss figure, revenue growth rate, guidance revision, or dilution details. A 22.7% single-day drop following an earnings release typically indicates either disappointing absolute results that contradict the positive framing in the headline, unmet consensus expectations, negative forward guidance, or concerns about share dilution that offset operational progress. Without the full earnings details, we cannot confirm which specific metric drove the sell-off, but the timing strongly implicates the earnings announcement itself rather than an unrelated external catalyst.
DEFSEC announced third-quarter fiscal 2026 results on August 13, and the 22% drop on August 14 suggests the earnings missed expectations or delivered negative guidance, though the headline text was truncated and specific numbers are unavailable.
The timing is strongly suggestive: a quarterly earnings announcement on August 13 UTC, followed immediately the next trading day by a significant 22% sell-off ranks DFSCW among the day's largest losers. This pattern is classic for a disappointing earnings release. The headline preview cuts off ("This a…"), so we cannot see the actual financial metrics, guidance commentary, or management discussion that triggered the market reaction. For a micro-cap trading at $0.03, negative surprises in revenue, losses, cash burn, or forward guidance can produce outsized percentage moves. Without access to the full earnings release, we cannot distinguish between a minor miss and a severe disappointment, but the magnitude of the drop and its immediate timing relative to earnings strongly implicates Q3 results as the primary catalyst rather than unrelated technical or rumor-driven selling.
Veritone reported Q2 earnings with 20% sequential revenue growth and debt reduction, but guidance was lowered due to public sector delays, likely triggering the 22% sell-off as investors repriced growth expectations downward.
Veritone released Q2 2026 results on August 13-14 showing revenue of $24.3 million, up 20% sequentially and 5% year-over-year, with strength in its Data Refinery and licensing segments. However, the earnings headlines explicitly note that management adjusted full-year guidance downward citing public sector delays. In growth-stage software and AI companies like Veritone, forward guidance cuts typically drive sharp sell-offs regardless of current-quarter beats, because the market reprices the multi-year revenue trajectory downward. The sequential revenue beat and cost-reduction actions are positive but appear to have been overshadowed by the guidance reduction. The 22% single-day decline ranks as the 25th biggest loser on NASDAQ, suggesting a material disappointment relative to prior expectations about public sector revenue timing and magnitude.
No news headlines were found in the last 48 hours for FGL, so the 21% drop cannot be attributed to a specific reported event. The move likely reflects either technical selling pressure, delayed news processing, or an undisclosed corporate event.
Without any recent news headlines, we cannot point to a concrete catalyst for FGL's sharp 21% decline. The stock is trading at $0.39, which suggests it may be a micro-cap or distressed equity vulnerable to thin-liquidity selloffs and technical momentum reversals. Possible categories of cause include: institutional redemptions or forced selling in the underlying fund or portfolio, a missed earnings or guidance event that has not yet appeared in Yahoo Finance feeds, or a delayed market reaction to news released outside the 48-hour window. Alternatively, this could reflect short covering reversals, options expiration pressure, or broader sector weakness in whatever industry FGL operates in, though without identifying the company's business segment, this remains speculative.
Medicus Pharma announced Q2 results and pipeline progress on August 12-13 with a $40 million financing raise, but the stock fell 20.77% the next day, suggesting investor disappointment with either the financial results, clinical metrics, or valuation concerns around the equity dilution from the r…
The company reported second quarter financial results and highlighted regulatory and clinical progress on its SkinJect and Teverelix programs while raising approximately $40 million through equity and debt financing. The headlines frame these as positive developments—key milestones, strengthened financial position, and pipeline execution support. However, the substantial 20.77% single-day decline suggests the market viewed something negatively. Possible explanations include: the equity raise diluting existing shareholders despite the capital raise size, clinical or regulatory results falling short of market expectations, cash burn rates or runway metrics disappointing investors relative to consensus, or the financing terms being unfavorable. Without access to the full earnings release, specific clinical data, or guidance commentary, the exact nature of investor disappointment cannot be precisely identified. Biotech stocks frequently gap down on earnings even with announced progress if financial metrics or safety signals disappoint.
No news headlines were found in the last 48 hours, so the 20% drop cannot be attributed to a specific announced catalyst; the decline is likely driven by technical selling, market-wide weakness, or undisclosed company developments.
The absence of recent news makes it impossible to pinpoint a definitive cause for the sharp 20% decline in MZYX.WT. This appears to be a warrant or derivative security based on the .WT ticker designation, which typically exhibits higher volatility than the underlying stock and can move sharply on technical factors, shifts in implied volatility, time decay, or changes in underlying asset value. Without headline-driven catalysts, possible drivers include broad market selloff pressure on speculative positions, liquidation by margin holders, changes in the underlying security's fundamentals that haven't yet appeared in public headlines, or simple technical breakdown. Warrant securities are also sensitive to changes in interest rates and volatility regimes that may not always generate explicit news coverage.
Hydrofarm announced second quarter 2026 results on the day of the 19.5% drop, indicating the earnings likely disappointed the market and triggered the sell-off.
The sole headline is Hydrofarm's Q2 2026 earnings announcement released on August 14, the same day as the sharp decline. The headline text itself is truncated and provides no details on revenue, earnings per share, guidance, or management commentary. However, the timing and magnitude of the drop—19.5% placing it in the top 29 losers of the day—strongly suggests the quarterly results fell short of investor expectations. Earnings misses, reduced forward guidance, margin compression, or disappointing growth rates are typical catalysts for such sharp single-day declines in growth-oriented industrial stocks like Hydrofarm. Without access to the full earnings release or analyst consensus estimates, we cannot pinpoint whether the miss was on profitability, revenue growth, or forward outlook, but the correlation between announcement timing and price action is clear.
No news headlines were reported in the last 48 hours for CWD, so the 19.36% decline cannot be attributed to a specific announced event; the move likely reflects either a delayed market reaction to previous news, technical selling, or sector headwinds.
The absence of recent news headlines makes direct attribution impossible. A nearly 20% single-day drop in a micro-cap stock trading at $0.53 typically indicates either a significant operational or financial announcement that has not yet appeared in mainstream financial feeds, a sharp technical breakdown following technical weakness, sector rotation out of small-cap or distressed equities, or potentially a delayed market reaction to news released before the 48-hour window. Without access to company press releases, SEC filings, social media, or other direct sources beyond the provided Yahoo Finance RSS, the specific catalyst remains unidentified. Penny stocks and micro-caps are also more prone to volatility from thin liquidity and institutional redemptions.
TSS Inc missed Q2 earnings and revenue estimates by significant margins (-37.5% and -32.3% respectively), offsetting positive momentum from a strategic pivot to higher-margin AI infrastructure and systems integration growth.
TSS reported second-quarter results on August 13-14 that disappointed on headline earnings and revenue, falling substantially short of consensus expectations despite operational bright spots. The company showed strong 46% year-over-year growth in systems integration revenue and a 640 basis point gross margin expansion tied to its AI infrastructure pivot, along with a $17 million investment to drive further AI data center technology revenue. However, the overall revenue decline due to lower procurement activity and the magnitude of the earnings miss appears to have overwhelmed investor sentiment. The market often reacts sharply to earnings surprises in the negative direction, particularly when absolute revenue falls, even when management articulates a credible strategic narrative around margin expansion and future growth drivers. The 19.29% single-day decline ranks TSSI as the 31st biggest loser, suggesting broad-based selling rather than isolated sector weakness.
WidePoint fell 19% despite beating Q2 earnings estimates because revenues missed expectations by 8.81%, driven by a drop in reselling and other services that overshadowed growth in carrier and managed services.
The headlines establish that WYY reported Q2 earnings that matched consensus expectations but delivered a revenue miss of 8.81 percent, a material shortfall on the top line. The company attributed this to lower reselling and other services revenues, which offset gains in carrier and managed services. While management highlighted a strengthened long-term outlook tied to a new Department of Homeland Security contract and positioned CWMS 3.0 as a 2027 growth engine with higher margins, the immediate quarterly miss appears to have triggered the sharp selloff. Market participants typically penalize revenue misses more severely than earnings misses, particularly when the shortfall reflects a structural weakness in a revenue segment rather than a temporary timing issue. The lack of forward guidance lift or a major contract value announcement may have disappointed investors expecting larger upside from the DHS award.
No financial news appeared in the last 48 hours to explain IVDA's 18.91% drop, so the decline likely reflects broader market weakness, technical selling, or undetected company-specific developments not yet published by major outlets.
The absence of any headlines in the Yahoo Finance RSS feed over the past two days makes it impossible to point to a specific catalyst for this large single-day loss. Micro-cap stocks like IVDA, trading near $0.42, are inherently volatile and often experience sharp price swings on light volume driven by technical factors, short covering, or rumor rather than reported news. The stock could have been caught in a sector rotation, experienced gap-down technical breakdown, or faced institutional redemptions. Alternatively, company news may have been released through non-traditional channels, on social media, or via a press release not yet picked up by major financial RSS feeds. Without confirmed headlines or knowledge of IVDA's specific business model and current valuation metrics, attributing this drop to fundamental weakness versus pure technical action remains speculative.
Xos missed revenue estimates by 61% in Q2 2026 despite operational improvements, triggering an 18.76% sell-off as investors repriced expectations for the electric vehicle maker's near-term growth trajectory.
The earnings release on August 13 reveals a mixed picture that likely explains the sharp decline. While Xos achieved record hub production, expanded gross margins substantially (GAAP margin to 31% from 11.8% year-over-year), and reduced operating expenses by 8.6%, the company delivered a revenue miss of 60.96% against estimates for Q2 2026. This massive revenue shortfall appears to have overshadowed the operational progress, as investors typically weight near-term revenue realization more heavily than margin expansion or future strategic initiatives like the Power Hub energy storage expansion. The headlines note order deferrals, which likely contributed to the revenue gap and signal demand uncertainty or customer pushback. Even though the company is navigating challenges with improving efficiency, the 61% revenue miss suggests the growth thesis has deteriorated materially in investor eyes.
No news headlines were found in the last 48 hours, so the 18.73% drop on BAOS cannot be attributed to a disclosed public event. The decline likely reflects either technical selling pressure, delayed reactions to prior announcements, or market sentiment shifts in a low-liquidity microcap stock.
Yahoo Finance's news feed returned zero headlines for BAOS in the past two days, which means no earnings report, regulatory action, guidance change, or major corporate announcement appears to have been publicly disclosed immediately before this sharp decline. However, BAOS is a microcap stock trading at $0.50, and such securities are often subject to heightened volatility, thin trading volume, and delayed or asymmetric news dissemination. The decline could reflect profit-taking after a prior run-up, forced liquidations due to margin calls or fund redemptions, short-seller activity targeting illiquid small-caps, or negative sentiment from news that circulated off the major RSS feeds. Without headline-level evidence, it is impossible to pinpoint the specific catalyst.
IMC Rare Earths dropped 18.32% with no news reported in the last 48 hours, making the specific catalyst unclear; the decline may reflect sector weakness, technical selling, or untracked material developments.
No headlines were available in the 48-hour window preceding this sharp 18 percent decline, which substantially limits the ability to pinpoint a root cause. Rare earth element stocks are sensitive to several factors including commodity price movements, regulatory shifts affecting mining operations, geopolitical developments impacting supply chains, and demand signals from the technology and defense sectors. The stock's positioning as the 36th biggest loser suggests this was a material repricing rather than isolated volatility. Without corroborating news, possible explanations span sector-wide headwinds affecting rare earth valuations, a company-specific announcement that bypassed major financial news feeds, technical capitulation following prior weakness, or delayed market reaction to information released outside the standard news cycle. The absence of any captured headline makes definitive attribution impossible.
PowerCompute (PWCM) dropped 18% on August 14, but no news headlines were available in the prior 48 hours to explain the move, making the specific catalyst unknown.
The absence of any news in the recent 48-hour window leaves the cause of this significant single-day drop unclear. For a micro-cap or small-cap stock like PWCM trading at $1.25, potential explanations could include a delayed announcement or earnings miss that has not yet been indexed by major news feeds, technical selling pressure from a breach of key support levels, or company-specific rumors circulating on social media or forums that precede formal disclosure. Alternatively, the move could reflect sector rotation out of smaller technology or infrastructure plays, or deterioration in a broader market condition during that trading session. Without access to intraday news, insider transaction activity, or real-time social media sentiment, the actual trigger remains speculative.
No news headlines are available in the last 48 hours, so the 17.88% decline likely stems from technical selling, a delayed announcement, or sector-wide pressure specific to this microcap warrant.
Sky Harbour Group Corporation is a microcap stock trading as a warrant instrument on NYSE. With no recent news available, the sharp one-day decline cannot be attributed to a specific company event or announcement. Warrant-based securities are particularly sensitive to underlying volatility, leverage effects, and liquidity dynamics. Possible drivers include technical selling in a thinly-traded name, broader sector weakness not captured in general market indices, expiration or roll-related mechanics affecting warrant holders, or a delayed announcement or regulatory filing that has not yet surfaced in public news feeds. Without access to intraday flow, insider filings, or real-time market data, identifying the precise catalyst is not possible. The stock's position as the 38th biggest loser suggests broader sector participation rather than an isolated event.
No news headlines were found in the last 48 hours to explain the 17.86% decline in KCHVR, so the cause remains unknown based on available public information.
KCHVR is a SPAC rights offering, which is a specialized security that typically trades at low prices and experiences significant volatility due to low liquidity and limited institutional interest. The absence of any news in the past 48 hours suggests the decline was not driven by a company announcement, regulatory event, or deal-related development. For rights offerings, declines can result from technical factors such as low trading volume, arbitrage unwinding, expiration pressure, or broader market weakness in blank-check securities. Without identifying headlines or structural catalysts specific to this issuer, the most probable causes are either technical selling in a thinly traded security or delayed market reaction to earlier news outside the 48-hour window.
SmartKem announced an executive appointment at its subsidiary Ferrox on August 13, but the news itself appears positive and does not directly explain the 17.71% decline; the drop likely reflects broader market sentiment, technical weakness, or undisclosed negative catalysts not captured in the pr…
The only headline provided is a positive personnel announcement—the appointment of Allen Palmiere as Executive Director and Chief Operating Officer of Ferrox, SmartKem's subsidiary. This type of announcement is typically neutral to slightly positive for a stock, as it signals operational management stability. However, this appointment does not align with a sharp 17.71% single-day decline. The disconnect suggests either that market reaction to the news was negative for reasons not explained in the snippet (e.g., market viewed the hire as inadequate or the subsidiary as underperforming), or that an entirely different catalyst drove the move—such as a delayed earnings miss, broader sector selloff, technical breakdown at a key support level, or unrelated negative news not captured in the 48-hour window provided. Without additional context about SmartKem's fundamentals, liquidity, or recent performance, pinpointing the cause is difficult.
ADI reported record Q2 revenue and resilient commercial demand, but the market appears to have reacted negatively to either softer forward guidance, ongoing residential weakness, or unmet expectations on profitability or margin expansion despite top-line strength.
The headlines confirm ADI announced Q2 2026 earnings on August 13 with record revenue and strong commercial segment performance. However, the news summaries provided are incomplete and do not include specific guidance statements, earnings-per-share results, margin trends, or management commentary that would typically explain a 17.71% single-day decline following an earnings release. The company explicitly notes residential audiovisual markets remain weak. In the specialty distribution sector, investors typically react sharply to changes in forward guidance, gross margin compression, or evidence that near-term demand is decelerating despite current quarter strength. Without access to the full earnings statement or call transcript, the most probable explanations are that management guided lower for Q3 or full-year, margins contracted despite record revenue, or the market had priced in significantly higher earnings and was disappointed by profitability metrics.
Hyperscale Data announced a sale of approximately 685 Bitcoin for $43 million to fund an AI data center pivot, triggering a sharp 17% decline as investors reassess the company's strategic shift away from pure Bitcoin mining.
On August 14, 2026, Hyperscale Data disclosed that it sold most of its Bitcoin holdings for roughly $43 million, with proceeds earmarked for an AI data center expansion. The company stated it plans to rebuild Bitcoin reserves through future mining and purchases. This dual announcement—liquidation of a core asset combined with a strategic pivot toward AI infrastructure—appears to have triggered significant selling pressure. Investors may interpret this move as dilutive to near-term returns, a signal of capital constraints, or skepticism about Bitcoin mining's relative attractiveness versus AI compute demand. The framing of the sale as temporary (with rebuild intentions) did not offset the immediate negative sentiment. The stock's rank as the 42nd biggest loser suggests broad market participation in the selloff rather than isolated weakness.
No news headlines were found in the last 48 hours to explain the 16.74% decline in APACR, a SPAC rights unit. The drop likely reflects either routine volatility in thinly-traded SPAC instruments or deteriorating sentiment toward the underlying acquisition target or deal structure.
The absence of any news in the prior 48 hours means we cannot point to a specific catalyst like an earnings report, regulatory action, or deal announcement. However, APACR is a rights offering from a Special Purpose Acquisition Company, a structure that is inherently sensitive to redemption flows, deal uncertainty, and sentiment shifts toward both the sponsor and the eventual target. These instruments trade in lower volumes than common shares and can experience sharp swings on technicals alone, or on broader market sentiment toward SPAC activity. The move could also reflect delayed disclosure of company-specific developments, market-wide deleveraging, or investor rotation out of blank-check vehicles. Without corroborating headlines, we cannot isolate the specific cause.
No news headlines were found in the last 48 hours, so the 16.67% drop in KFIIR cannot be attributed to a specific announced event. The decline likely reflects either technical selling, fluctuations in the underlying SPAC's value, or market-wide sentiment shifts affecting blank-check equity.
KFIIR is a rights offering from K&F Growth Acquisition Corp. II, a Special Purpose Acquisition Company structure. Rights offerings are derivative securities whose value is sensitive to the underlying SPAC's stock performance, redemption dynamics, and the perceived probability of deal completion. Absent any news announcement in the provided headlines, the decline could stem from several structural factors typical of this security class: broad SPAC sector weakness, a drop in the underlying common stock, increased redemption risk, or shifts in investor appetite for blank-check vehicles. Rights holders face dilution and termination risk if the SPAC fails to close a business combination by its deadline. Without access to the underlying company's recent price action or SPAC-specific announcements, pinpointing the precise trigger is difficult, though technical trading and macro sentiment toward SPACs remain plausible drivers.
Mobix Labs announced a transformational rare earth elements acquisition on August 13, but the stock dropped 16.33% the next day, suggesting investor skepticism about deal terms, financing concerns, or valuation dilution rather than enthusiasm for the strategic expansion.
Mobix Labs signed a definitive agreement to acquire Special Project Delivery, Inc., positioning itself in rare earth elements and critical minerals—a strategically important sector aligned with national security interests. The announcement came with an investor call scheduled for 4:15pm ET on August 13. However, the stock fell sharply the following day despite what the company framed as a transformational deal. This disconnect between positive M&A news and negative price action typically reflects investor concerns about deal structure, including potential equity dilution, unclear financing details, valuation of the target, or integration risks. Without access to the full investor call transcript or details on acquisition price and terms, we cannot isolate the specific concern, but the timing suggests the market's initial read on deal economics was negative despite the strategic rationale.
No news headlines were found in the last 48 hours, so the 16.33% drop likely stems from a sector-wide decline, technical selling, or a delayed announcement not yet captured in the RSS feed.
AcelRx is a small-cap biopharmaceutical company with limited liquidity, making it prone to sharp single-day moves on thin trading volume even without breaking news. The absence of headlines in the past 48 hours suggests the catalyst was either (1) a company announcement or clinical/regulatory update that has not yet propagated to Yahoo Finance RSS, (2) sector rotation out of small-cap biotech or specialty pharmaceuticals, or (3) technical selling following a prior run-up. Small-cap pharma stocks are particularly sensitive to FDA decisions, trial data readouts, partnership announcements, and cash runway concerns. Without access to the company's own press releases or SEC filings from the past 48 hours, it is impossible to determine the precise trigger, though a regulatory or clinical setback would be the most typical catalyst for a drop of this magnitude in this stock category.
No news headlines were published in the last 48 hours, so the 16.24% drop likely reflects broader market weakness, sector rotation away from EV stocks, or company-specific concerns not captured in major financial media coverage.
Faraday Future is a pre-revenue or low-revenue electric vehicle startup that has historically been volatile and subject to sentiment swings, funding concerns, and execution delays. The absence of any news in the past 48 hours does not rule out catalyst activity; FFIE could have faced a delayed market reaction to older announcements, adverse social media chatter, analyst downgrades not yet captured in RSS feeds, short-seller reports, or general de-risking in speculative EV names. Alternatively, the move could be purely technical or driven by intraday momentum. Without current headlines, we cannot pinpoint the specific trigger, only that the magnitude of the decline suggests either negative sentiment development or broader sector pressure hitting a stock with high beta.
Freight Technologies announced a fleet management integration today, but the positive press release does not explain the 16.2% single-day drop; the decline likely reflects a broader market, sector, or company-specific headwind unrelated to this news.
The only recent headline is a product integration announcement from Fleet Rocket TMS with Highway to automate carrier compliance and onboarding, released on the same day as the stock's 16.2% drop. This type of operational update is typically neutral to modestly positive for software and logistics technology companies, not a catalyst for a material single-day loss. The timing coincidence suggests the news did not trigger the decline. Possible explanations include deteriorating market sentiment toward transportation technology stocks, a delayed earnings miss or negative guidance revision announced separately, short covering reversal, or a broader market selloff that day. Without additional headlines addressing valuation, profitability, contracts, or forward guidance, the specific cause remains unclear.
Paysafe dropped 16% despite beating Q2 revenue expectations and matching earnings, likely driven by disappointing forward guidance, margin pressures, and high leverage concerns that overshadowed the operational beat.
Paysafe reported second-quarter results on August 13 with revenue above Wall Street forecasts and earnings matching expectations, initially gaining 0.8%. However, the stock reversed sharply the following day, closing down 16%. The headlines indicate the company faces significant headwinds: margin pressures, a high-leverage environment, and what appears to be a softer earnings outlook despite revenue strength. The news also mentions debt reduction efforts and a preliminary settlement of legacy litigation, suggesting the company is burdened by both financial and legal obligations. While management reaffirmed full-year guidance, the apparent gap between revenue performance and earnings trajectory—combined with visible operational challenges—appears to have triggered substantial selling. The motorsport partnership announcement on August 14 arrived too late to prevent the decline and likely had minimal influence on equity markets.
Algorhythm Holdings reported strong Q2 2026 earnings with 161% YoY revenue growth to $3.0M, but the stock fell 15.84%, suggesting the market either expected even stronger results, has concerns about profitability or burn rate, or is responding to forward guidance.
The company announced second quarter 2026 results on August 14, 2026, showing impressive top-line growth of 161% year-over-year and 25% sequential revenue increase to $3.0 million. This headline alone would typically warrant a positive reaction for an AI-powered logistics company. However, the stock declined sharply, which suggests the market's reaction was driven by factors not visible in the headline snippet itself. Common reasons for sell-offs despite strong revenue growth include disappointing earnings per share, negative operating cash flow, reduced forward guidance, commentary on margin compression, or disclosure of significant cash burn. Without access to the full earnings release, balance sheet metrics, management guidance, or analyst commentary, the exact reason for the decline cannot be determined from available evidence.